Browse

Claims

Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.

1 claim

Niacin (nicotinic acid, vitamin B3) as a lipid-modifying drug: its HDL-raising and lipid effects, safety (flushing, glycemia), and cardiovascular outcomes in trials, especially as add-on to statins (e.g., AIM-HIGH, HPS2-THRIVE). Not for niacin as a dietary nutrient in general nutrition contexts, nor for other lipid-lowering drug classes.

Niacin added to statin therapy failed to reduce cardiovascular events

UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular disease Statin therapyimportance · minorImportance 0.25, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Contribute

If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim entirely, propose it below. A proposal is reviewed on its merits; accepted claims are matched against the graph and enter it with their reasoning on record.